Where We Stand

Introduction
Position statements
Congressional testimony
Comments
Resources

Introduction

The Alzheimer's Association takes a stand on critical policy issues and works to change laws, regulations and public programs to accomplish our mission. This section provides summaries of where we stand on current issues and makes specific recommendations for policy makers.

This section contains a summary of our overall public policy positions, official National Board statements on particular issues, certain past actions through Congressional testimony, and comments to federal agencies made on behalf of the Association.

Position statements

The Alzheimer’s Association has statements on a wide variety of topics and issues that have surfaced in relation to Alzheimer’s disease. The position statements listed below have been approved by Association national board of directors, our Medical and Scientific Advisory Committee or board committees.

Genetic Testing (1 page)
Adopted April 2008

Statement Regarding Treatment of Behavioral and Psychiatric Symptoms of Alzheimer’s Disease (4 pages)
Adopted March 2008

Human Stem Cell Research (1 page)
Adopted June 2004

Driving (1 page)
Adopted October 2001

Use of Animals in Research (1 page)
Revised in April 1999

Drug Formularies (1 page)
Adopted November 1997

Ethical Issues in Dementia Research (2 pages)
Adopted May 1997

Treatment of Individuals with Advanced Dementia (1 page)
Adopted May 1988

Congressional testimony on behalf of the Alzheimer's Association

Testimony related to care and services

03/20/07	Harry Johns, president and CEO, Alzheimer's Association, Chicago, Ill.
03/10/05	David Hyde Pierce, Los Angeles, California
04/27/04	Stephen McConnell, senior vice president, Advocacy & Public Policy, Alzheimer's Association, Washington, D.C.

Testimony related to research funding

03/20/07	Marilyn Albert, Ph.D., director, Division of Cognitive Neuroscience Department of Neurology, Johns Hopkins University School of Medicine, co-director, Johns Hopkins Alzheimer's Disease Research Center, Baltimore Maryland
03/20/07	Dr. Sam Gandy, chair, Alzheimer’s Association Medical & Scientific Advisory Council
05/03/05	David Hyde Pierce, Los Angeles, California
05/03/05	Dr. Sam Gandy, vice chair, Alzheimer’s Association Medical & Scientific Advisory Council
05/11/04	Stephen McConnell, vice president for Advocacy and Public Policy, Alzheimer's Association, Washington, D.C.
03/30/04	Testimony of Susie Means, Alzheimer Advocate, Massillon, Ohio
03/23/04	Phyllis Campbell, president, Urban League of Lancaster County, Pa.
03/23/04	Shelley Fabares, national board member, Alzheimer's Association, Studio City, Calif.
03/23/04	Sheldon Goldberg, president & CEO, Alzheimer’s Association, Chicago, Ill.
03/23/04	Dennis Kroucik, Elyria, Ohio
03/23/04	Johnny Orr, West Des Moines, Iowa
03/23/04	Dr. David Snowden, Professor In the Department of Neurology & the Sanders-Brown Center on Aging at the University Of Kentucky, Lexington, Ky.
03/22/04	Constantine G. Lyketsos, M.D., M.H.S., Johns Hopkins, Baltimore, Md.

Testimony from caregivers and persons with Alzheimer's

03/20/07	Marilyn Blum, Alzheimer Advocate from Owings Mills, Maryland
05/03/05	Meryl Comer Board Member, National Capital Area Chapter Alzheimer Association
05/03/05	Julie Noonan Lawson, Alzheimer Advocate from East Sandwhich, Massachusetts
05/03/05	Dr. Bernard Reisman, Alzheimer Advocate fom West Newton, Massachusetts
03/10/05	Remarks of Karen Rivera, Alzheimer Advocate from St. Peter’s, Missouri

Comments to federal agencies and Congress

6/12/06	Comments on Access to Alzheimer Drugs Through Medicare Prescription Drug Plans to Centers for Medicare and Medicaid Services
6/15/05	Comments on Medicaid Reform Report from the National Governor's Association (NGA)
12/30/04	Draft Medicare Formulary Review Comments to Centers for Medicare and Medicaid Services
10/04/04	Comments on Medicare Prescription Drug Program
10/04/04	Executive Summary of Comments
09/24/04	Initial Preventive Physical Examination to Centers for Medicare and Medicaid Services
09/17/04	Medicare Prescription Drug: Formulary Guidelines Comments to United States Pharmacopeia
05/28/02	Feeding Assistants Regulations to Centers for Medicare and Medicaid Services

Additional information

Association media/news releases
Media | Current Releases